India to Cambodia: Ambroxol Export Trade Route

To import Ambroxol formulations into Cambodia, the following approvals and registrations are necessary:

2. Importer Licensing: Companies intending to import pharmaceuticals must obtain an Import-Export Pharmaceutical License from the MOH. This license is a prerequisite for engaging in the importation and distribution of pharmaceutical products within Cambodia. (cambodiantr.gov.kh)

4. Product Shelf Life: Imported pharmaceuticals must have a minimum remaining shelf life of 18 months upon arrival in Cambodia to ensure product efficacy and safety.

5. Labeling Requirements: All pharmaceutical products must comply with Cambodian labeling regulations, which may include the requirement to affix a vignette on the product packaging. (cambodiantr.gov.kh)

Indian manufacturers exporting Ambroxol formulations to Cambodia must adhere to the following quality and GMP standards:

1. GMP Certification: Manufacturing facilities must possess valid GMP certificates recognized by the MOH. These certificates should be issued by a competent authority and demonstrate compliance with international GMP standards.

2. Facility Registration: Foreign pharmaceutical manufacturers are required to register their manufacturing facilities with the Cambodian MOH. This involves submitting detailed documentation about the manufacturing process, quality control measures, and GMP compliance.

3. Inspections: While specific details about recent inspections or regulatory actions by the National DRA (ASEAN MRA) against Indian pharmaceutical companies are not readily available, it is imperative for exporters to maintain compliance with Cambodian regulations to avoid potential penalties or import restrictions.

As of March 2026, there have been no publicly documented regulatory changes, new guidelines, mutual recognition agreements, or policy shifts affecting Indian pharmaceutical exports to Cambodia within the past 18 months. However, it is crucial for exporters to stay informed about potential regulatory updates by regularly consulting official communications from the Cambodian MOH and the DDF.

In summary, importing Ambroxol formulations into Cambodia necessitates thorough compliance with the country's pharmaceutical registration and importation requirements, including product registration, importer licensing, adherence to GMP standards, and ensuring proper documentation and labeling.

As of 2024, Cambodia's pharmaceutical market has been experiencing steady growth, driven by increased healthcare spending and efforts to expand universal health coverage. Respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and bronchitis, are prevalent, contributing to the demand for mucolytic agents like Ambroxol. While specific market size data for Ambroxol formulations in Cambodia is limited, the country's reliance on imports indicates a significant demand. Domestic pharmaceutical manufacturing is developing but remains limited, necessitating substantial imports to meet healthcare needs.

Cambodia applies a 0% import duty on pharmaceutical products classified under HS Code 30, which includes finished formulations containing Ambroxol. Additionally, all imports are subject to a 10% Value Added Tax (VAT). Cambodia's participation in the ASEAN Free Trade Area (AFTA) provides preferential tariff rates for member countries; however, since pharmaceutical products already benefit from a 0% import duty, the impact of AFTA on these imports is minimal. There are no specific anti-dumping duties imposed on pharmaceutical imports, including Ambroxol formulations.

India is a major supplier of Ambroxol formulations to Cambodia, accounting for approximately 7.3% of India's total Ambroxol formulation exports, valued at $1.1 million USD. Other countries, such as China and various European Union member states, also export pharmaceutical products to Cambodia. However, India's competitive pricing and established trade relationships have solidified its position as a leading supplier. While exact market share data for Ambroxol imports from countries other than India is not readily available, India's significant contribution underscores its dominance in this segment. Pricing comparisons indicate that Indian pharmaceutical products are generally more cost-effective than those from European manufacturers, providing a competitive edge in the Cambodian market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are certified by international regulatory bodies. As of March 2024, India had 396 facilities registered with the U.S. Food and Drug Administration (FDA) under the Generic Drug User Fee Amendments (GDUFA), the highest number globally.

The production of finished dosage forms containing Ambroxol, such as tablets, capsules, and syrups, benefits from India's cost-effective manufacturing processes. The country's large-scale production capabilities and economies of scale enable competitive pricing without compromising quality. Additionally, numerous Indian pharmaceutical companies hold certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP), ensuring adherence to international quality standards.

When comparing Ambroxol formulation exports from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers offer Ambroxol formulations at competitive prices due to cost-efficient production methods and economies of scale. Chinese manufacturers also provide low-cost formulations; however, the quality and regulatory compliance can vary. EU manufacturers typically offer higher-priced formulations, reflecting stringent regulatory standards and higher production costs.

• Quality Perception: Indian pharmaceutical products are generally well-regarded for their quality, supported by numerous WHO-GMP and FDA-approved facilities. Chinese products have faced scrutiny over quality concerns, necessitating thorough supplier verification. EU products are perceived as high-quality due to strict regulatory oversight.

• Regulatory Acceptance in Cambodia: Cambodia's Ministry of Health recognizes and accepts pharmaceutical products from countries with stringent regulatory authorities, including India and the EU. Chinese products may require additional scrutiny to meet local regulatory standards.

• Supply Reliability Track Record: Indian manufacturers have a strong track record of reliable supply chains, supported by robust infrastructure and regulatory compliance. Chinese manufacturers have improved supply reliability but may still face challenges related to regulatory compliance. EU manufacturers offer reliable supply chains but at higher costs.

The India-Cambodia supply chain for Ambroxol formulations is robust, supported by India's substantial manufacturing capacity. Indian facilities are equipped to produce large volumes of finished dosage forms, including tablets, capsules, and syrups. Packaging and cold chain capabilities are well-developed, ensuring product integrity during transit.

There have been no significant supply disruptions reported in recent years. Indian manufacturers maintain a strong regulatory compliance track record, with numerous facilities holding WHO-GMP and FDA approvals. Top Indian formulation manufacturers continue to expand their capacities to meet growing global demand.

For Cambodian buyers sourcing Ambroxol formulations from India, consider the following recommendations:

• Dual-Sourcing Strategy: Engage with multiple Indian suppliers to mitigate risks associated with supply disruptions and ensure a consistent supply of Ambroxol formulations.

• Minimum Order Quantities (MOQs): Indian manufacturers typically have flexible MOQs, but it's advisable to confirm specific requirements with each supplier to align with procurement needs.

• Payment Terms: Common payment terms in India-Cambodia pharmaceutical trade include Letters of Credit (LC) and Telegraphic Transfers (TT). Negotiating favorable terms can enhance cash flow management.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, verification of regulatory certifications (e.g., WHO-GMP, FDA approvals), and assessment of quality control systems to ensure supplier reliability.

• Regulatory Compliance: Ensure that selected suppliers comply with both Indian and Cambodian regulatory requirements, facilitating smooth importation and market entry.

By implementing these strategies, Cambodian buyers can establish a reliable and cost-effective supply chain for Ambroxol formulations from India.

By adhering to this comprehensive approach, Cambodian companies can ensure the selection of reliable Indian suppliers for Ambroxol formulations, safeguarding product quality and regulatory compliance.